Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study.
about
Aflibercept for neovascular age-related macular degenerationManagement of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled TrialsAflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degenerationMaculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: A case report.Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications.One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement.Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan.Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment.The impact of different anti-vascular endothelial growth factor treatment regimens on reducing burden for caregivers and patients with wet age-related macular degeneration in a single-center real-world Japanese setting.Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI) study.Effect of aflibercept in patients with age-related macular degeneration.The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration
P2860
Q24186157-46F31782-6F21-49E7-AD59-E9F9B7672A8AQ26767095-FCB40342-42A2-41F6-A006-97B6B32756EAQ26771522-F1050FCD-EDB5-437C-9EE7-DF11C32B40A7Q33760560-A0F0C7A5-71D5-47FD-A0C2-1DF2F5AA4EF5Q36013973-A4DB5AD2-8E06-4AAC-80F4-90467D608CCAQ36955686-E509CCA6-1AB4-47B1-8602-EEF317259ACCQ39323991-4F1BAD5E-E1A4-4E04-9EAE-1CE4FCE4472BQ42426609-3C5DA460-05F5-4378-96BC-2BF71CCAF061Q47095567-388111D2-44A7-4B0A-B6B2-DD95735E4291Q51133647-078C694B-436E-4F79-9987-EEC9AD4F3540Q55057323-276B727A-AF27-4B3A-B966-72C1257E366CQ58766295-7A558CBE-DDA7-4C84-BE26-ACB64FE90B81
P2860
Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of intravi ...... subgroup of the VIEW 2 study.
@ast
Efficacy and safety of intravi ...... subgroup of the VIEW 2 study.
@en
Efficacy and safety of intravi ...... subgroup of the VIEW 2 study.
@nl
type
label
Efficacy and safety of intravi ...... subgroup of the VIEW 2 study.
@ast
Efficacy and safety of intravi ...... subgroup of the VIEW 2 study.
@en
Efficacy and safety of intravi ...... subgroup of the VIEW 2 study.
@nl
prefLabel
Efficacy and safety of intravi ...... subgroup of the VIEW 2 study.
@ast
Efficacy and safety of intravi ...... subgroup of the VIEW 2 study.
@en
Efficacy and safety of intravi ...... subgroup of the VIEW 2 study.
@nl
P2093
P2860
P50
P1476
Efficacy and safety of intravi ...... e subgroup of the VIEW 2 study
@en
P2093
Christian Simader
Hiroko Terasaki
Koichi Nishijo
Miki Honda
Mitsuko Yuzawa
Olaf Sowade
Tetsushi Komori
Tomohiro Iida
VIEW 2 Investigators
Yuichiro Ogura
P2860
P356
10.1136/BJOPHTHALMOL-2014-305076
P407
P577
2014-08-08T00:00:00Z